APOB and homozygous familial hypercholesterolemia: In conclusion, ANGPTL3 inhibition with evinacumab markedly increases IDL and LDL apoB catabolic rates in this small study of 4 patients with hoFH, suggesting that evinacumab lowers LDL-C predominantly by increasing apoB-containing lipoprotein clearance from the circulation.